Eagle IP to Attend INTA 2026 Annual Meeting in London

2 May 2026

We are pleased to announce that Jennifer Che, Managing Director of Eagle IP, will be traveling to London from May 2 to May 6, 2026 in conjunction with the International Trademark Association (INTA) 2026 Annual Meeting..

If you or your team will be attending INTA2026 or will be in London during the first week of May, Jennifer would welcome the opportunity to meet for a coffee or a scheduled briefing. Please contact us to coordinate a time during the conference week.

Our Past Events

Yolanda Wang attended the 1st China Pharmaceutical Innovation Conference

22 July 2026

Pauli Wong as a Guest speaker for “Entrepreneurial Workshop” in Poly U

16 June 2026

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2026 Patent Firms Ranking List

5 June 2026

Eagle IP Achieves Top Ranking in 2026 IAM Patent 1000

2 June 2026

Eagle IP to Participate in AIPLA 2026 Spring Meeting in San Francisco

8 May 2026

Eagle IP has been named as the Winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026

8 May 2026

Recommended Insights

What Kind of Damage Awards Can You Get in China?

16 June 2022

Is it worth filing for a patent in China? What kind of damage awards can you get? Pharma companies care more about injunction than damage awards, since it’s quite unlikely that any damage award can compensate for the large amounts of money that may be lost for patent infringement. Chinese courts often issue injunctions in […]

China’s Newest Examination Guidelines: Novelty and Inventive Step for Compounds (Part II)

29 April 2021

This is Part II of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

A Detailed Dive into China’s New Patent Term Extension Provisions

11 December 2020

This article is a part of a larger article that highlights the newest draft implementation rules of the new Chinese Patent Law. This particular article takes a detailed dive into the patent term extension/adjustment provisions. One of the biggest and most exciting provisions in the newly amended patent law is patent term extension for delay […]

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

12 December 2023

Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]